NR 565 Advanced Pharmacology Midterm Exam Prep |
Complete 150 Q&A Question Bank Bundle with
Verified Answers & Rationales (Chamberlain Across
Lifespan)
1. A patient stabilized on Warfarin (Coumadin) for atrial fibrillation is diagnosed with
a severe fungal infection and initiated on an intensive course of oral Amiodarone.
Amiodarone acts as a potent cytochrome P450 (CYP2C9) enzyme inhibitor.
What is the expected physiological impact of this interaction, and what clinical
adjustment must the APRN make?
A) Warfarin metabolism will accelerate, decreasing the INR; the Warfarin dose must be
increased.
B) Warfarin metabolism will be inhibited, increasing the INR and bleeding risk; the
Warfarin dose must be reduced.
C) Amiodarone will bind to albumin, displacing Warfarin and instantly inducing renal
failure.
D) The drug interaction is clinically insignificant because Warfarin bypasses hepatic
first-pass metabolism.
Correct Answer: B) Warfarin metabolism will be inhibited, increasing the INR and
bleeding risk; the Warfarin dose must be reduced.
, Rationale: CYP450 inhibitors slow down the metabolic breakdown of substrate drugs
(like Warfarin), leading to accumulation and increased toxicity risks. Because
Amiodarone inhibits CYP2C9 (the primary pathway for active S-warfarin clearance), the
patient's INR will spike dangerously unless the Warfarin dose is proactively decreased
by 30% to 50% and monitored closely.
Why others are incorrect: A describes the action of a CYP450 inducer (e.g., Rifampin
or Phenytoin). C and D are factually inaccurate statements regarding the mechanism of
action and clearance pathways of these medications.
Question 2: Foundational Principles / Steady State Calculations
Question: An APRN prescribes a new daily maintenance medication with a
documented elimination half-life of 12 hours. Assuming the patient maintains perfect
compliance, approximately how long will it take for this drug to reach a steady-state
plasma concentration?
A) 12 to 24 hours
B) 48 to 60 hours (2 to 2.5 days)
C) 7 to 10 days
D) Exactly 5 hours
Correct Answer: B) 48 to 60 hours (2 to 2.5 days)
Rationale: As a fundamental pharmacological rule, it takes approximately 4 to 5
elimination half-lives for a drug to reach a steady state (where the rate of drug
administration equals the rate of drug elimination).
\(\text{Steady\ State}=4\text{\ to\ }5\times t_{1/2}\)
\(4\times 12\text{\ hours}=48\text{\ hours}\)
\(5\times 12\text{\ hours}=60\text{\ hours}\)
Why others are incorrect: A represents only 1 to 2 half-lives, meaning the drug is still
heavily accumulating. C overestimates the time required based on the provided 12-hour
metric. D confuses a half-life metric with the number of half-lives required.
Question 3: Legalities of Prescribing / DEA Scheduling
Question: A patient with severe chronic pain requires a new prescription for
Oxycodone/Acetaminophen (Percocet). According to the federal Controlled Substances
Act, under which DEA schedule does this drug fall, and what are the specific prescribing
restrictions?
A) Schedule III; can be refilled up to 5 times within a 6-month period.
B) Schedule II; no refills are permitted, and a new written or secure electronic
prescription is required for every fill.
C) Schedule IV; can be verbally ordered over the phone by an assistant without
restriction.
D) Schedule V; can be sold over-the-counter in most states without a prescription.
Correct Answer: B) Schedule II; no refills are permitted, and a new written or
secure electronic prescription is required for every fill.
Rationale: Schedule II drugs have a high potential for abuse which may lead to severe
psychological or physical dependence, but they have an accepted medical use. Federal
, law strictly prohibits refills on Schedule II prescriptions to force continuous monitoring
and re-evaluation.
Why others are incorrect: A describes the rules for Schedule III and IV medications. C
is an illegal practice maneuver for Schedule II narcotics. D describes minor cough
suppressants or anti-diarrheal mixtures containing low-dose codeine.
Question 4: Geriatric Pharmacology / Anticholinergic Dangers
Question: An 84-year-old male is brought to the clinic by his family due to a sudden
onset of confusion, visual hallucinations, dry mouth, and urinary retention. Upon
reviewing his new medications, the APRN notes he was recently prescribed
Amitriptyline for diabetic neuropathy. This clinical presentation is a classic example of:
A) Normal age-related cognitive decline
B) An acute anticholinergic toxidrome highlighted by the AGS Beers Criteria
C) Acute withdrawal from a short-acting benzodiazepine
D) A therapeutic response indicating optimal central nervous system saturation
Correct Answer: B) An acute anticholinergic toxidrome highlighted by the AGS
Beers Criteria
Rationale: Amitriptyline is a tricyclic antidepressant with profound anticholinergic
properties. The Beers Criteria explicitly lists it as a high-risk medication for older adults
because its anti-acetylcholine mechanism triggers central and peripheral toxicities:
memory impairment, confusion, dry mouth, blurred vision, constipation, urinary
retention, and tachyarrhythmias.
Why others are incorrect: A underplays an acute drug toxicity as a baseline aging
event. C is incorrect because the patient is exhibiting signs of active anticholinergic
toxicity, not sedative-hypnotic withdrawal. D is an dangerous clinical misinterpretation.
Question 5: Pediatric Pharmacology / Neonatal Excretion Risks
Question: When calculating medication doses for a 3-week-old neonate, the APRN
knows that the infant's glomerular filtration rate (GFR) and renal tubular mechanisms
are structurally immature compared to an adult. What is the immediate prescribing
consequence of this physiological difference?
A) Excretion of renally cleared drugs will be significantly prolonged, necessitating longer
dosing intervals or lower doses.
B) Drugs will be cleared rapidly, requiring a doubling of the standard adult dose.
C) Oral absorption of lipid-soluble medications will be completely blocked.
D) Neonates are completely immune to nephrotoxic medication exposures.
Correct Answer: A) Excretion of renally cleared drugs will be significantly
prolonged, necessitating longer dosing intervals or lower doses.
Rationale: At birth, renal blood flow and GFR are significantly lower than adult levels,
reaching full maturation closer to 1 year of age. Consequently, drugs that rely on renal
filtration for elimination (e.g., aminoglycoside antibiotics) accumulate rapidly in
neonates, increasing the risk of systemic toxicities unless the dosing interval is
expanded.
, Why others are incorrect: B would result in lethal drug toxicity. C describes an
absorptive phase issue rather than an excretory clearance principle. D is completely
false; neonates are highly vulnerable to drug-induced nephrotoxicity.
Question 6: Prescribing Mechanics / First-Pass Elimination
Question: An APRN is reviewing why a patient requires Morphine Sulfate 30 mg when
taken orally, but only requires Morphine Sulfate 4 mg when administered intravenously
to achieve the exact same level of pain control. This discrepancy is driven by which
pharmacological mechanism?
A) High protein binding capacity of oral tablets
B) Hepatic first-pass metabolism
C) Gastric acid degradation of active molecules
D) Glomerular filtration rate differences
Correct Answer: B) Hepatic first-pass metabolism
Rationale: Oral medications enter the GI tract, are absorbed into the mesenteric
circulation, and travel directly to the liver via the portal vein before reaching systemic
circulation. For drugs with a high extraction ratio (like morphine), hepatic enzymes
metabolize a massive fraction of the drug during this initial pass, drastically reducing its
systemic bioavailability. IV administration bypasses this portal circulation entirely.
Why others are incorrect: A, C, and D are not the primary mechanisms responsible
for the massive, predictable difference between oral and intravenous therapeutic dose
ranges for opioid agonists.
Question 7: Endocrinology / Metformin Safety Boundaries
Question: Prior to initiating Metformin for a 56-year-old patient with new-onset Type 2
Diabetes, which specific laboratory metric must the APRN evaluate to safely prevent a
black box warning risk of fatal lactic acidosis?
A) Serum lipase level
B) Estimated Glomerular Filtration Rate (eGFR)
C) Thyroid-stimulating hormone (TSH)
D) Serum uric acid level
Correct Answer: B) Estimated Glomerular Filtration Rate (eGFR)
Rationale: Metformin is cleared entirely by the kidneys unchanged. If a patient has
significant renal impairment, Metformin accumulates in the tissues and disrupts
mitochondrial oxidation, heavily provoking the accumulation of lactic acid. Metformin is
strictly contraindicated if the eGFR falls below 30 mL/min/1.73m².
Why others are incorrect: A evaluates the pancreas (relevant for pancreatitis with
GLP-1 RAs). C measures thyroid health. D tracks gout risks. None of these drive the
metabolic clearance parameters of biguanide therapy.
Question 8: Women’s Health / Pharmacokinetics in Pregnancy
Question: During pregnancy, a woman's physiological maternal blood volume expands
significantly, and her glomerular filtration rate (GFR) increases by up to 50%. How do
these structural alterations affect the pharmacokinetics of highly water-soluble
medications?
Complete 150 Q&A Question Bank Bundle with
Verified Answers & Rationales (Chamberlain Across
Lifespan)
1. A patient stabilized on Warfarin (Coumadin) for atrial fibrillation is diagnosed with
a severe fungal infection and initiated on an intensive course of oral Amiodarone.
Amiodarone acts as a potent cytochrome P450 (CYP2C9) enzyme inhibitor.
What is the expected physiological impact of this interaction, and what clinical
adjustment must the APRN make?
A) Warfarin metabolism will accelerate, decreasing the INR; the Warfarin dose must be
increased.
B) Warfarin metabolism will be inhibited, increasing the INR and bleeding risk; the
Warfarin dose must be reduced.
C) Amiodarone will bind to albumin, displacing Warfarin and instantly inducing renal
failure.
D) The drug interaction is clinically insignificant because Warfarin bypasses hepatic
first-pass metabolism.
Correct Answer: B) Warfarin metabolism will be inhibited, increasing the INR and
bleeding risk; the Warfarin dose must be reduced.
, Rationale: CYP450 inhibitors slow down the metabolic breakdown of substrate drugs
(like Warfarin), leading to accumulation and increased toxicity risks. Because
Amiodarone inhibits CYP2C9 (the primary pathway for active S-warfarin clearance), the
patient's INR will spike dangerously unless the Warfarin dose is proactively decreased
by 30% to 50% and monitored closely.
Why others are incorrect: A describes the action of a CYP450 inducer (e.g., Rifampin
or Phenytoin). C and D are factually inaccurate statements regarding the mechanism of
action and clearance pathways of these medications.
Question 2: Foundational Principles / Steady State Calculations
Question: An APRN prescribes a new daily maintenance medication with a
documented elimination half-life of 12 hours. Assuming the patient maintains perfect
compliance, approximately how long will it take for this drug to reach a steady-state
plasma concentration?
A) 12 to 24 hours
B) 48 to 60 hours (2 to 2.5 days)
C) 7 to 10 days
D) Exactly 5 hours
Correct Answer: B) 48 to 60 hours (2 to 2.5 days)
Rationale: As a fundamental pharmacological rule, it takes approximately 4 to 5
elimination half-lives for a drug to reach a steady state (where the rate of drug
administration equals the rate of drug elimination).
\(\text{Steady\ State}=4\text{\ to\ }5\times t_{1/2}\)
\(4\times 12\text{\ hours}=48\text{\ hours}\)
\(5\times 12\text{\ hours}=60\text{\ hours}\)
Why others are incorrect: A represents only 1 to 2 half-lives, meaning the drug is still
heavily accumulating. C overestimates the time required based on the provided 12-hour
metric. D confuses a half-life metric with the number of half-lives required.
Question 3: Legalities of Prescribing / DEA Scheduling
Question: A patient with severe chronic pain requires a new prescription for
Oxycodone/Acetaminophen (Percocet). According to the federal Controlled Substances
Act, under which DEA schedule does this drug fall, and what are the specific prescribing
restrictions?
A) Schedule III; can be refilled up to 5 times within a 6-month period.
B) Schedule II; no refills are permitted, and a new written or secure electronic
prescription is required for every fill.
C) Schedule IV; can be verbally ordered over the phone by an assistant without
restriction.
D) Schedule V; can be sold over-the-counter in most states without a prescription.
Correct Answer: B) Schedule II; no refills are permitted, and a new written or
secure electronic prescription is required for every fill.
Rationale: Schedule II drugs have a high potential for abuse which may lead to severe
psychological or physical dependence, but they have an accepted medical use. Federal
, law strictly prohibits refills on Schedule II prescriptions to force continuous monitoring
and re-evaluation.
Why others are incorrect: A describes the rules for Schedule III and IV medications. C
is an illegal practice maneuver for Schedule II narcotics. D describes minor cough
suppressants or anti-diarrheal mixtures containing low-dose codeine.
Question 4: Geriatric Pharmacology / Anticholinergic Dangers
Question: An 84-year-old male is brought to the clinic by his family due to a sudden
onset of confusion, visual hallucinations, dry mouth, and urinary retention. Upon
reviewing his new medications, the APRN notes he was recently prescribed
Amitriptyline for diabetic neuropathy. This clinical presentation is a classic example of:
A) Normal age-related cognitive decline
B) An acute anticholinergic toxidrome highlighted by the AGS Beers Criteria
C) Acute withdrawal from a short-acting benzodiazepine
D) A therapeutic response indicating optimal central nervous system saturation
Correct Answer: B) An acute anticholinergic toxidrome highlighted by the AGS
Beers Criteria
Rationale: Amitriptyline is a tricyclic antidepressant with profound anticholinergic
properties. The Beers Criteria explicitly lists it as a high-risk medication for older adults
because its anti-acetylcholine mechanism triggers central and peripheral toxicities:
memory impairment, confusion, dry mouth, blurred vision, constipation, urinary
retention, and tachyarrhythmias.
Why others are incorrect: A underplays an acute drug toxicity as a baseline aging
event. C is incorrect because the patient is exhibiting signs of active anticholinergic
toxicity, not sedative-hypnotic withdrawal. D is an dangerous clinical misinterpretation.
Question 5: Pediatric Pharmacology / Neonatal Excretion Risks
Question: When calculating medication doses for a 3-week-old neonate, the APRN
knows that the infant's glomerular filtration rate (GFR) and renal tubular mechanisms
are structurally immature compared to an adult. What is the immediate prescribing
consequence of this physiological difference?
A) Excretion of renally cleared drugs will be significantly prolonged, necessitating longer
dosing intervals or lower doses.
B) Drugs will be cleared rapidly, requiring a doubling of the standard adult dose.
C) Oral absorption of lipid-soluble medications will be completely blocked.
D) Neonates are completely immune to nephrotoxic medication exposures.
Correct Answer: A) Excretion of renally cleared drugs will be significantly
prolonged, necessitating longer dosing intervals or lower doses.
Rationale: At birth, renal blood flow and GFR are significantly lower than adult levels,
reaching full maturation closer to 1 year of age. Consequently, drugs that rely on renal
filtration for elimination (e.g., aminoglycoside antibiotics) accumulate rapidly in
neonates, increasing the risk of systemic toxicities unless the dosing interval is
expanded.
, Why others are incorrect: B would result in lethal drug toxicity. C describes an
absorptive phase issue rather than an excretory clearance principle. D is completely
false; neonates are highly vulnerable to drug-induced nephrotoxicity.
Question 6: Prescribing Mechanics / First-Pass Elimination
Question: An APRN is reviewing why a patient requires Morphine Sulfate 30 mg when
taken orally, but only requires Morphine Sulfate 4 mg when administered intravenously
to achieve the exact same level of pain control. This discrepancy is driven by which
pharmacological mechanism?
A) High protein binding capacity of oral tablets
B) Hepatic first-pass metabolism
C) Gastric acid degradation of active molecules
D) Glomerular filtration rate differences
Correct Answer: B) Hepatic first-pass metabolism
Rationale: Oral medications enter the GI tract, are absorbed into the mesenteric
circulation, and travel directly to the liver via the portal vein before reaching systemic
circulation. For drugs with a high extraction ratio (like morphine), hepatic enzymes
metabolize a massive fraction of the drug during this initial pass, drastically reducing its
systemic bioavailability. IV administration bypasses this portal circulation entirely.
Why others are incorrect: A, C, and D are not the primary mechanisms responsible
for the massive, predictable difference between oral and intravenous therapeutic dose
ranges for opioid agonists.
Question 7: Endocrinology / Metformin Safety Boundaries
Question: Prior to initiating Metformin for a 56-year-old patient with new-onset Type 2
Diabetes, which specific laboratory metric must the APRN evaluate to safely prevent a
black box warning risk of fatal lactic acidosis?
A) Serum lipase level
B) Estimated Glomerular Filtration Rate (eGFR)
C) Thyroid-stimulating hormone (TSH)
D) Serum uric acid level
Correct Answer: B) Estimated Glomerular Filtration Rate (eGFR)
Rationale: Metformin is cleared entirely by the kidneys unchanged. If a patient has
significant renal impairment, Metformin accumulates in the tissues and disrupts
mitochondrial oxidation, heavily provoking the accumulation of lactic acid. Metformin is
strictly contraindicated if the eGFR falls below 30 mL/min/1.73m².
Why others are incorrect: A evaluates the pancreas (relevant for pancreatitis with
GLP-1 RAs). C measures thyroid health. D tracks gout risks. None of these drive the
metabolic clearance parameters of biguanide therapy.
Question 8: Women’s Health / Pharmacokinetics in Pregnancy
Question: During pregnancy, a woman's physiological maternal blood volume expands
significantly, and her glomerular filtration rate (GFR) increases by up to 50%. How do
these structural alterations affect the pharmacokinetics of highly water-soluble
medications?
